Triple immunofluorescence staining for prediction of relapse in childhood precursor B acute lymphoblastic leukaemia.
In this study we describe a fast and sensitive method using three-colour immunofluorescence for the detection of cells with phenotypes that are rare in normal bone marrow (BM) but occur frequently in children with precursor B acute lymphoblastic leukaemia. We show that, in the first year after initiation of therapy, in 17/18 patients (10 patients were analysed after first diagnosis and nine patients after first BM relapse; one patient was analysed on both occasions) the percentage of CD10+ CD19+ cells and CD20- CD22+ cells in the CD34+ cell population indicated the likelihood of relapse. A suppression of cells expressing these phenotypes after initiation of therapy was followed by an outgrowth of normal precursor B cells after 12 months. Therefore this early test for impending relapse (which occurred 10-28 months after starting chemotherapy) was only applicable in the first year after beginning the treatment. However, despite this predictive value, comparison of fluorescence data with PCR results obtained from the same BM sample indicated that only a subpopulation of the CD34+ CD10+ CD19+ and CD34+ CD20- CD22+ cells above the determined threshold value represented malignant cells. A large prospective study to confirm the predictive value of this three-colour immunofluorescence assay is warranted.
Vervoordeldonk
S F
SF
Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam.
Merle
P A
PA
Behrendt
H
H
Steenbergen
E J
EJ
Van Leeuwen
E F
EF
Van den Berg
H
H
Von dem Borne
A E
AE
Van der Schoot
C E
CE
Slaper-Cortenbach
I C
IC
D002051:Burkitt Lymphoma / Q000175:diagnosis*; D002648:Child; D002675:Child, Preschool; D005455:Fluorescent Antibody Technique / Q000379:methods; D005544:Forecasting; D006801:Humans; D016133:Polymerase Chain Reaction; D011289:Preleukemia / Q000175:diagnosis*; D012008:Recurrence; D012680:Sensitivity and Specificity